A new treatment approach is changing the standard of care

AACR — 1 July 2025

“For the First Time in Decades, a New Treatment Option for Locally Advanced Head and Neck Cancer”

This is less sensational but arguably more important. The FDA approved perioperative pembrolizumab following Phase III evidence, introducing a new treatment approach for locally advanced head and neck cancer. AACR described it as the first new therapeutic approach in more than 20 years for this group of patients.

This article shows that immunotherapy isn't simply an experimental idea anymore—it is changing how some head and neck cancers are treated.